Natalizumab in pediatric multiple sclerosis

[MSUK]

Natalizumab in paediatric multiple sclerosis: results of a cohort of 55 cases

Abstract

BACKGROUND: Limited information is available on the use of natalizumab (NA) in pediatric multiple sclerosis (ped-MS) patients.

OBJECTIVE: The purpose of this study was to describe the long-term effects of NA in a large cohort of active ped-MS patients.

METHODS: Patients with definite ped-MS were treated with NA if in the previous year they had experienced at least two relapses or a severe relapse with incomplete recovery while on immunomodulating treatment, or at least two relapses and new magnetic resonance imaging (MRI) lesions regardless of any prior treatment.... Read More - http://www.ms-uk.org/index.cfm/paediatric